71145-35-2

Basic information

• Product Name: succinyl-Gly-Gly-OBzl
• Synonyms: succinyl-Gly-Gly-OBzl
• CAS NO: 71145-35-2
• Molecular Weight: 322.318
• Mol File: 71145-35-2.mol

Chemical Properties

• CAS DataBase Reference: succinyl-Gly-Gly-OBzl(CAS DataBase Reference)
• NIST Chemistry Reference: succinyl-Gly-Gly-OBzl(71145-35-2)
• EPA Substance Registry System: succinyl-Gly-Gly-OBzl(71145-35-2)

Safety Data

• Hazardous Substances Data: 71145-35-2(Hazardous Substances Data)

Upstream product

• 108-30-5 succinic acid anhydride 
• 1738-82-5 glycylglycine benzyl ester p-toluene sulfonate salt 
• 31972-51-7 N-(tert-butoxycarbonyl)glycylglycine benzyl ester 
• 1738-76-7 glycine benzyl ester p-toluenesulfonic acid salt 
• 7797-34-4 benzylglycylglycinate hydrochloride 

Downstream Products

• 807344-35-0 C₅₁H₆₁N₁₁O₁₁ 
• 807344-32-7 [2-(3-{[(methylcarbamoylmethyl-carbamoyl)-methyl]-carbamoyl}-propionylamino)-acetylamino]-acetic acid benzyl ester 
• 147984-97-2 succinyl bis 

Relevant articles and documents

A bivalent ligand (KDN-21) reveals spinal δ and κ opioid receptors are organized as heterodimers that give rise to δ1 and δ2 phenotypes. Selective targeting of δ-κ heterodimers

In view of recent pharmacological studies suggesting the existence of δ-κ opioid receptor heterodimers/oligomers in the spinal cord, we have synthesized and evaluated (intrathecally in mice) a series of bivalent ligands (KDN series) containing κ and δ antagonist pharmacophores. Pharmacological and binding data have provided evidence for the bridging of spinal δ-κ receptor heterodimers by KDN-21 and for their identification as δ1 and κ2. The selectivity profile of KDN-21 and the apparent absence of coupled δ 1-κ2 phenotypes in the brain suggest a new approach for targeting receptors.